<DOC>
	<DOCNO>NCT01817452</DOCNO>
	<brief_summary>Trial evaluate efficacy dual blockade two anti-HER2 agent without chemotherapy backbone within ADAPT trial .</brief_summary>
	<brief_title>A Prospective , Randomized Multicenter , Open-label Comparison Preoperative Combination Trastuzumab Pertuzumab With Without Concurrent Taxane Chemotherapy Given Twelve Weeks Patients With Operable HER2+/HR- Breast Cancer Within ADAPT Protocol</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient , age diagnosis 18 year ( consider patient 70 year ADAPT Elderly ) Histologically confirm unilateral primary invasive carcinoma breast Clinical T1 T4 ( except inflammatory breast cancer ) All clinical N ( cN ) No clinical evidence distant metastasis ( M0 ) Known HR status HER2 status ( local pathology ) Tumor block available central pathology review Performance Status ECOG ≤ 1 KI ≥ 80 % Negative pregnancy test ( urine serum ) within 7 day prior start induction treatment premenopausal patient Written inform consent prior begin specific protocol procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement The patient must accessible treatment followup Additional Inclusion criterion participation HR/HER2+ subprotocol : Confirmed ER PR negative HER2+ central pathology Clinical cT1c T4ac ( participation patient tumor &gt; cT2 strongly recommend ) All clinical N ( participation patient cN0 , least cT1c strongly recommend ) Patients must qualify neoadjuvant treatment LVEF &gt; 50 % ; LVEF within normal limit institution measure echocardiography normal ECG ( within 42 day prior induction treatment ) Known hypersensitivity reaction compound incorporated substance Prior malignancy diseasefree survival &lt; 10 year , except curatively treat basalioma skin , pTis cervix uteri Nonoperable breast cancer include inflammatory breast cancer Previous concurrent treatment cytotoxic agent reason consultation sponsor Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry Male breast cancer Concurrent pregnancy ; patient childbearing potential must implement highly effective ( less 1 % failure rate ) nonhormonal contraceptive measure study treatment Breast feeding woman Sequential breast cancer Reasons indicate risk poor compliance Patient able consent Additional Exclusion Criteria participation HER2+/HR subprotocol : Known polyneuropathy ≥ grade 2 Severe relevant comorbidity would interact application cytotoxic agent participation study Inadequate organ function ( e.g . hepatic impairment , pulmonary disease , etc . ) Uncompensated cardiac function ( current unstable ventricular arrhythmia require treatment , history symptomatic CHF NYHA class IIIV ) , history myocardial infarction unstable angina pectoris within 6 month enrollment , history severe hypertension , CAD coronary artery disease ) Severe dyspnea Abnormal blood value : Thrombocytopenia &gt; CTCAE grade 1 Increases ALT/AST &gt; CTCAE grade 1 Hypokalaemia &gt; CTCAE grade 1 Neutropenia &gt; CTCAE grade 1 Anaemia &gt; CTCAE grade 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>